The meeting hosted clinicians, academic experts in the field of outcome measurement, representatives from eight pharmaceutical companies, funding agencies, and community stakeholders. The meeting’s goals were: 1) to discuss strategies for promoting more effective clinical trials of medications to address autism core and associated symptoms and 2) to develop consensus regarding the best clinical assessments to determine whether a treatment has been effective in clinical trials. The group discussed the following key points to be addressed in future initiatives: (A) Since there are currently a number of very good outcome measures that are appropriate for clinical trials, developing consensus on a group of standard measures is a key next step. FDA approval of a medication requires consensus outcome measures. Among the questions that were discussed in regards to standard measures were: 1) what are the most sensitive outcome measures, 2) what is the best setting to measure outcome, and 3) from whom should the outcome data be collected (parents, teachers, clinicians)? (B) There are opportunities to develop new outcome measures based on promising technologies that provide measures of biological change. Experts in new technologies that can make use of devices such as the iPhone to collect outcome data in real time and in real world settings also offered several promising ideas. (C) Long-term success of those conducting clinical trials with people with ASD requires closer collaboration between parents, clinicians, and the basic scientists who are developing treatment targets.